Hua Medicine (Shanghai) Ltd. (2552.HK)
- Previous Close
1.510 - Open
1.520 - Bid 1.500 x --
- Ask 1.550 x --
- Day's Range
1.500 - 1.570 - 52 Week Range
1.290 - 3.380 - Volume
1,005,000 - Avg. Volume
1,087,940 - Market Cap (intraday)
1.478B - Beta (5Y Monthly) 1.60
- PE Ratio (TTM)
-- - EPS (TTM)
-0.240 - Earnings Date Mar 28, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
3.59
Hua Medicine (Shanghai) Ltd. operates as a drug development company that focuses on therapies for the treatment of diabetes in China. It develops Dorzagliatin or HMS5552, an oral drug for the treatment of Type 2 Diabetes (T2D); and Dorzagliatin in combination with Metformin, Sitagliptin, and Empagliflozin for treatment of T2D. The company also offers Dorzagliatin in combination with Pioglitazone for NASH; in combination with GLP-1 for Alzheimer diseases; and in combination with insulin for late stage T2D and Type 1 Diabetes. In addition, it is developing mGLUR5 for the treatment of Parkinson's disease; and Fructokinase Inhibitor for Metabolic disease. The company was incorporated in 2011 and is based in Beijing, China.
www.huamedicine.com177
Full Time Employees
December 31
Fiscal Year Ends
Sector
Related News
Performance Overview: 2552.HK
Trailing total returns as of 4/19/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 2552.HK
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 2552.HK
Valuation Measures
Market Cap
1.48B
Enterprise Value
78.69M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
17.80
Price/Book (mrq)
13.50
Enterprise Value/Revenue
1.03
Enterprise Value/EBITDA
-0.39
Financial Highlights
Profitability and Income Statement
Profit Margin
-275.73%
Return on Assets (ttm)
-14.84%
Return on Equity (ttm)
-110.96%
Revenue (ttm)
76.61M
Net Income Avi to Common (ttm)
-211.23M
Diluted EPS (ttm)
-0.240
Balance Sheet and Cash Flow
Total Cash (mrq)
1.46B
Total Debt/Equity (mrq)
165.85%
Levered Free Cash Flow (ttm)
259.48M
Research Analysis: 2552.HK
Analyst Price Targets
Fair Value
No Fair Value available for this ticker